A 2021 meta-analysis of the SUSTAIN and PIONEER trials found that GLP-1 users have a 266% increased risk of developing deep vein thrombosis
A randomized trial in early Parkinson's disease tested tesofensine at 0.25 mg, 0.5 mg, and 1.0 mg as monotherapy [2]
Studies Drug price negotiation program is a successwith caveats The first round of CMS drug price negotiation program resulted in critical savings for beneficiaries though savings vary per drug, a new study in the New England Journal of Medicine argues
8 A newer antidiabetic drug class, sodium-glucose cotransporter-2 inhibitors, has a very low risk of drug interactions
Many of my clients in the Fully Optimized Health community stack KLOW with BPC-157 protocols for gut healing or add it to their existing TB-500 regimens for injury recovery
Honestly, though, for most tendon and ligament-focused studies, the Sub-Q method is perfectly sufficient and carries a lower risk profile